The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Of course there is a reason for the bounce.
The FCA approval for AMGO is a rubber stamp for the short term loan market as a whole and will benefit everybody in the sector.
troajan
yes
1.00 paid
a no reason bounce....best to sell into them,if you can catch the high.
gla
I remember paying 8p here - definitely got multibag potential after Amgo news
??
Multi bags here. Gla
AMIGO valued 30X higher
Both have a huge loan boom
Whatever AMIGO rises - NSF should 5 fold the increase with a market cap of 1.5m
Don’t forget NSF - NSF should get a far bigger rise off the back of it
Read the RNS, it says the whole market sector will benefit
NSF have a huge loan book and with only a 1.5m market cap
Grab your NSF cheapies before the market realises the whole sector are going to benefit
Any chance this dies well cause of AMGO or not related?
took a little profit for other value plays.
well done if you bought last week. :)
I can work out the % increase if it ever went into the 0.30s BIT it didn't.
Plus it's 0.70p.(well 0.66p) to buy not sell!
Overall conclusion your talking BS about this share
it went a bit lower, order was filled.
on ask now at .70 so work it out
any ways may sell and move to another value
Lowest it hit was 0.42p and lowest to buy was 0.44p so that's garbage.
Keep trying
have done really well here so, up 60% on on very good size, should have bought more, but hey ho there are other plays to think about.
we had a lot of bashing the lows last week. :)
well.
Probably, confused!
magmanus_49
You bought In the low 30s and sold 50% up.?
well nearly bagged up 50%
bought in low 30's - and bagged what is the fuss about down here ??
kids here
Im a small shareholder in this organisation. In all honesty the negligence shown here appears criminal. Listed in 2015 basically as a Shell shareholder funds have been wiped out without even a whimper of competence from the board. There has been silence for over a year. When capital appeared short some three or 4 years ago a rights issue at say 10p could have saved the company from this death fall . There has been nothing. Statements saying how well some parts of the business are doing yet no dealing with the real corporate issues that shareholders need. The Board of directors should be made to pay for the gross negligence. Fortunately I've not lost a lot but I'm angry as to why it seems no one brings them to account
Any EverydayLoans employees need to start looking for other jobs… It’s NOT ‘business as usual’, it’s over…
Before anything this is wholly and solely down to poor management before the FCA ever intervened, they should hang their heads in shame.
Well Gillespie, Wiggins & the shambles that is the Leadership team have finally finished the job. Sad for all those new recruits duped into joining a ‘growing/thriving’ business. Shame on you for putting livelihoods at risk…
So that’s pretty much the end of NSF as a public company. Gillespie has finished the demolition job started by Van Kueffler and taken them into the 99% club.
Was only an opinion, DYOR and all that but, I posted in May ‘21 that Alchemy might want to push NSF into Administration to acquire Everyday on the cheap and in June ‘21 that Guarantor Loans and Everyday were the same legal entity so had to deal with this as a joint matter.
And now we hear that if the fund raise fails (which Alchemy can ensure as they are on the board), money might be found to settle joint claims and take Everyday private, wiping out investors on the way. No surprise but it’s still incredibly disappointing.
Unsure how a private operation would get FCA approval as it feels like a Phoenix business. But I guess that won’t be our concern.
I don’t want to agree as I am a shareholder, but I think this is a dead duck now. The FCA have screwed us. The poor management has screwed us. The amount of money that has been pumped into NSF is unbelievable with no shareholder returns whatsoever. All the directors will be ok though. Still get paid and get a bonus probably. They should never be able to run a company again as far as I’m concerned.
· Without the successful completion of the Capital Raise, the Group remains balance sheet insolvent and the Group's ability to remain a going concern is subject to material uncertainties. However, the Directors continue to believe there is a reasonable prospect of resolving this position through the Process and the Capital Raise.
They're not bringing this back to life....DONE, FINISHED